A FIRST-IN-HUMAN TRIAL OF HSTC810 (ANTI-BTN1A1 AB), A NOVEL IMMUNE CHECKPOINT WITH A MUTUALLY EXCLUSIVE EXPRESSION WITH PD-1/PD-L1, IN PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS

被引：1
|
作者：
Lee, Soohyeon [1 ]
Shin, Sangjoon [2 ]
Howie, Lynn [3 ]
Jung, Hyunjin [4 ]
Yoo, Steven [3 ,4 ]
Hong, David [5 ]
机构：
[1] Korea Univ, Anam Hosp, Seoul, South Korea
[2] Yonsei Canc Ctr, Seoul, South Korea
[3] STCube Pharmaceut Inc, Gaithersburg, MD USA
[4] STCube Inc, Seoul, South Korea
[5] MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0740
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
740
引用
收藏
页码：A773 / A773
页数：1
相关论文
共 50 条
  • [21] Human Herpesvirus and the Immune Checkpoint PD-1/PD-L1 Pathway: Disorders and Strategies for Survival
    Murata, Takayuki
    MICROORGANISMS, 2021, 9 (04)
  • [22] Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors
    Miguel Sampedro-Núñez
    Ana Serrano-Somavilla
    Magdalena Adrados
    José M. Cameselle-Teijeiro
    Concepción Blanco-Carrera
    José Manuel Cabezas-Agricola
    Rebeca Martínez-Hernández
    Elena Martín-Pérez
    José Luis Muñoz de Nova
    José Ángel Díaz
    Rogelio García-Centeno
    Javier Caneiro-Gómez
    Ihab Abdulkader
    Roberto González-Amaro
    Mónica Marazuela
    Scientific Reports, 8
  • [23] Patterns of PD-1 PD-L1 and PD-L2 expression in pediatric solid tumors.
    Pinto, Navin R.
    Park, Julie R.
    Murphy, Erin
    Yearley, Jennifer
    McClanahan, Terri
    Annamalai, Lakshmanan
    Hawkins, Douglas S.
    Rudzinski, Erin R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
    Zhang, Yiru
    Yao, Qigu
    Pan, Yong
    Fang, Xinru
    Xu, Haoying
    Zhao, Tingxiao
    Zhu, Guangqi
    Jiang, Tianan
    Li, Shibo
    Cao, Hongcui
    CANCERS, 2023, 15 (03)
  • [25] Whole-body PD-L1 and PD-1 PET: First-in-human experience.
    Leung, David
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 20 - 21
  • [26] A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.
    Yap, Timothy A.
    Papadopoulos, Kyriakos P.
    LoRusso, Patricia
    Wong, Deborah J. L.
    Hu-Lieskovan, Siwen
    Holz, Josefin-Beate
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
    Koopmans, Iris
    Hendriks, Djoke
    Samplonius, Douwe F.
    van Ginkel, Robert J.
    Heskamp, Sandra
    Wierstra, Peter J.
    Bremer, Edwin
    Helfrich, Wijnand
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [28] A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
    Koopmans, Iris
    Samplonius, Douwe F.
    van Ginkel, Robert J.
    Wierstra, Peter J.
    Heskamp, Sandra
    Bremer, Edwin
    Helfrich, Wijnand
    CANCER RESEARCH, 2018, 78 (13)
  • [29] Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1
    Patera, Andriani C.
    Drewry, Anne M.
    Chang, Katherine
    Beiter, Evan R.
    Osborne, Dale
    Hotchkiss, Richard S.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2016, 100 (06) : 1239 - 1254
  • [30] Cancer patients can be categorized by a uniform and mutually exclusive pattern of expression of PD-1 or PD-L1 on their tumor infiltrating T lymphocytes
    Marabelle, Aurelien
    Mouraud, Severine
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345